Association Between Human Epidermal Growth Factor Receptor 2-Low Status and Time to Development of Brain Metastases Among Patients With Breast Cancer: A Retrospective Cohort Study
Our findings suggest that among patients with HR+ breast cancer, HER2-low status was associated with shorter TTBM compared with HER2-zero status. In a subset of patients for whom HER2 status of the PBC was available, HER2-low status was associated with shorter PBC-TTBM, irrespective of HR status. This study suggests a previously unrecognized association between HER2-low status and timing of BrM development.
Authors
- Veronika Moravan
- Arjun Sahgal (ORCID: https://orcid.org/0000-0001-7991-8970)
- Rania Chehade (ORCID: https://orcid.org/0009-0000-2535-0275)
- Kevin Yijun Fan
- Katarzyna J. Jerzak (ORCID: https://orcid.org/0000-0002-3995-0308)
- Ellen Warner (ORCID: https://orcid.org/0000-0002-7956-6845)
- Ítalo Fernandes (ORCID: https://orcid.org/0000-0002-9254-6136)
Institutions
- Statistics Canada (CA)
- Sunnybrook Health Science Centre (CA)
- University of Toronto (CA)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1200/po-24-00641
- Citations
- 2
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04